On a per-share basis, the
The biopharmaceutical company posted revenue of
Amarin shares have risen 6% since the beginning of the year. The stock has decreased 34% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from
Copyright by Automated Insights, Inc. All rights reserved., source